IGF1 and acromegaly: Pasireotide has demonstrated statistically significant and clinically relevant efficacy vs long-acting octreotide in medically naïve patients with active acromegaly, which is predominantly driven by greater reductions in IGF-I with pasireotide vs octreotide (C2305) (10), and vs long-acting octreotide/lanreotide Autogel in patients previously treated with these agents (C2402) prior to receiving pasireotide therapy (11).